[go: up one dir, main page]

PT666914E - Nova proteina ligando da selectina p - Google Patents

Nova proteina ligando da selectina p

Info

Publication number
PT666914E
PT666914E PT94900380T PT94900380T PT666914E PT 666914 E PT666914 E PT 666914E PT 94900380 T PT94900380 T PT 94900380T PT 94900380 T PT94900380 T PT 94900380T PT 666914 E PT666914 E PT 666914E
Authority
PT
Portugal
Prior art keywords
selectin
selectin ligand
disclosed
ligand protein
seq
Prior art date
Application number
PT94900380T
Other languages
English (en)
Inventor
Dianne S Sako
Xiao-Jia Chang
Geertruida M Veldman
Glenn R Larsen
Gray D Shaw
Original Assignee
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc
Publication of PT666914E publication Critical patent/PT666914E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
PT94900380T 1992-10-23 1993-10-22 Nova proteina ligando da selectina p PT666914E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96566292A 1992-10-23 1992-10-23
US11260893A 1993-08-26 1993-08-26

Publications (1)

Publication Number Publication Date
PT666914E true PT666914E (pt) 2004-04-30

Family

ID=26810148

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94900380T PT666914E (pt) 1992-10-23 1993-10-22 Nova proteina ligando da selectina p

Country Status (9)

Country Link
EP (2) EP1396542B1 (pt)
JP (3) JPH08502886A (pt)
AT (2) ATE501254T1 (pt)
AU (1) AU677261B2 (pt)
CA (2) CA2497857C (pt)
DE (2) DE69334350D1 (pt)
DK (2) DK1396542T3 (pt)
PT (1) PT666914E (pt)
WO (1) WO1994010309A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
AU770883B2 (en) * 1996-08-30 2004-03-04 Genetics Institute, Llc P-selectin ligand proteins
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes
AU2975599A (en) * 1998-02-27 1999-09-15 Genetics Institute Inc. P-selectin ligand protein including tetrameric fusion proteins
IL142717A0 (en) * 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
CA2404310A1 (en) * 2000-03-24 2001-10-04 Meike Lorenz A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
AU2001249515B2 (en) * 2000-03-27 2006-10-05 Genetics Institute, Llc Methods for purifying highly anionic proteins
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
AU2003232994B2 (en) * 2002-04-22 2009-07-23 Recopharma Ab Lewis Y epitope modified polypeptide, or mucin fusion polypeptide, tumor vaccines
AU2003255337A1 (en) * 2002-07-31 2004-02-23 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
EP1960419B1 (en) 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
WO2009053358A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
JP5493234B2 (ja) * 2008-05-15 2014-05-14 国立大学法人 岡山大学 Ｐｓｇｌ−１阻害によるメタボリックシンドロームの予防及び治療法
CN106659784B (zh) * 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
CN111201038A (zh) 2017-01-11 2020-05-26 戊瑞治疗有限公司 Psgl-1拮抗剂及其用途
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
TW201945393A (zh) 2018-03-21 2019-12-01 美商戊瑞治療有限公司 在酸性pH結合至VISTA之抗體
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2097765T3 (es) * 1989-10-20 1997-04-16 New England Medical Center Inc Un sistema de inhibicion del enlazado de celulas intermediado por padgem.
DK0714912T3 (da) * 1990-07-17 2003-02-03 Univ Oklahoma Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140
IE914102A1 (en) 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
JPH06508823A (ja) * 1991-03-11 1994-10-06 ニュー　イングランド　メディカル　センター　ホスピタルズ，インコーポレイテッド ２，６シアル酸成分を含むインヒビターによるｐａｄｇｅｍ媒介相互作用の阻害方法
JP3859697B2 (ja) * 1991-05-06 2006-12-20 ジェネンテック・インコーポレーテッド セレクチンリガンド
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof

Also Published As

Publication number Publication date
JPH08502886A (ja) 1996-04-02
DK0666914T3 (da) 2004-04-13
JP3668242B2 (ja) 2005-07-06
AU677261B2 (en) 1997-04-17
CA2147623A1 (en) 1994-05-11
ATE256182T1 (de) 2003-12-15
CA2497857C (en) 2009-05-26
CA2147623C (en) 2005-05-03
EP1396542A3 (en) 2004-05-06
DE69333346T2 (de) 2004-10-07
EP0666914A1 (en) 1995-08-16
WO1994010309A1 (en) 1994-05-11
DK1396542T3 (da) 2011-06-06
JP4237711B2 (ja) 2009-03-11
EP1396542A2 (en) 2004-03-10
CA2497857A1 (en) 1994-05-11
AU5538894A (en) 1994-05-24
ATE501254T1 (de) 2011-03-15
EP1396542B1 (en) 2011-03-09
EP0666914B1 (en) 2003-12-10
JP2005170954A (ja) 2005-06-30
DE69333346D1 (de) 2004-01-22
JP2004194664A (ja) 2004-07-15
DE69334350D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
PT666914E (pt) Nova proteina ligando da selectina p
CA2263889A1 (en) P-selectin ligand proteins
ES8306324A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ATE184052T1 (de) Gdf-1 und uog1 proteine
TW327194B (en) Novel amyloid precursor proteins and methods of using same
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
DE69130506D1 (de) Nukleotidsequenzen kodierend für ein humanes protein mit angiogenetisch-regulatorischen eigenschaften
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
WO1995030001A3 (en) Novel p-selectin ligand protein
IL75963A (en) Omega interferon polypeptides of type 1,n-glycosylated derivatives thereof with omega interferon activity,polynucleotide sequences encoding the omega interferon polypeptides,methods for the preparation of the polypeptides and pharmaceutical compositions containing them
DE3582895D1 (de) Peptid, dessen herstellung und benutzung.
NZ222466A (en) Hexa to deca peptides capable of stimulating the proliferation of myelopoietic stem cells
ZA896980B (en) Peptide compounds
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
DE69115270D1 (de) Protein mit fibroblasten-wachstumsfaktor-rezeptoraktivität.
DE69534738D1 (de) Leukocyten-aktivierender Faktor
WO1990000179A3 (fr) Nouvelles proteins, adn les codant et leur usage
DE68913802D1 (de) Thymosin und TNF-kodierende DNA.
JPS5775960A (en) Purified polypeptide
WO1999043834A3 (en) P-selectin ligand protein, including tetrameric fusion proteins
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen